Eupraxia Pharmaceuticals Overhauls Leadership Ahead of Critical EoE Trial Data
Event summary
- Dr. Jeff Millard joins as EVP, Technical Operations on July 13, 2026, bringing 25 years of CMC and regulatory experience.
- Dr. Alex Therien promoted to EVP, Research & Development to drive portfolio expansion.
- Company relocates headquarters from Victoria to Vancouver/Seattle hubs for clinical operations scaling.
- Amanda Malone steps down as CSO effective July 10, 2026 after transition period.
The big picture
Eupraxia's executive reshuffle signals transition from clinical-stage to late-stage development, critical for Diffusphere™ technology commercialization. The leadership team's combined experience in CMC, regulatory strategy, and portfolio expansion positions the company for Phase 3 scaling ahead of Q4 EoE trial readouts. Relocation to major biotech hubs reflects strategic pivot toward commercial operations.
What we're watching
- Clinical Milestones
- How Q4 2026 RESOLVE trial interim data impacts EoE market positioning.
- Operational Scaling
- Whether Vancouver/Seattle hubs can support Phase 3 commercialization timelines.
- Pipeline Expansion
- The pace of new inflammatory joint and oncology indications under Dr. Therien's leadership.
Related topics